Here is an excerpt from the abstract:
“Epithelial ovarian cancer (EOC) is one of the most common cancers in the female reproductive system and deadliest gynecological cancer in the United States. Standard treatments by surgery and platinum-based chemotherapy are not satisfied for the patients with high risk of relapse. Advances in molecular biology for EOC development have brought several targeted therapies to benefit recurrent patients. Poly-ADP-ribose polymerase inhibitors (PARPi) may be one of the most successful classes of targeted therapies with three approved medicines. For better clinical outcomes and more comprehensive disease management of EOC, more novel classes of targeted therapies are needed.”
The full article can be viewed here: http://www.eurekaselect.com/168576/article
Dr. Nikoulin has 14 years of academic and 16 years of drug discovery and development experience serving as a project leader and team leader/principal investigator, as well as experience working in GMP and GLP compliant labs. Dr. Nikoulin has extensive knowledge and experience in small molecule, peptide, and protein formulation development, and lipid- / polymer-based micro- and nanoparticle-targeted drug delivery systems.
Prior to IRISYS, Dr. Nikoulin directed research and development projects in the areas of cardiovascular, inflammatory, and metabolic diseases at Avanir Pharmaceuticals. His varied responsibilities ranged from setting up and supervising the laboratories to coordinating the efforts of cross-functional teams, and academic and industry partners.
We here at IRISYS are proud to have Dr. Nikoulin as part of our organization. We encourage him to continue with his research endeavors and look forward to him sharing it with the rest of the community.